Phase 2
Completed N=38
The Role of Endothelin in Pulmonary Hypertension
Source: ClinicalTrials.gov NCT00759408 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Oct 2018
Primary outcomePrimary: Pulmonary Vascular Resistance (PVR) — 64; 119; 67; 46 dyn*sec/cm^5
Summary
The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pulmonary Vascular Resistance (PVR) |
64; 119; 67; 46; 85 | — |
| SECONDARY Systemic Vascular Resistance (SVR) |
1368; 1050; 1351; 1069; 828 | — |
| SECONDARY Mean Pulmonary Artery Pressure (PAP) |
10; 15; 10; 9; 14 | — |
| SECONDARY Cardiac Output (CO) |
5.3; 6.7; 5.2; 6.4; 8.3 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers or known diagnosis of pulmonary hypertension
Exclusion Criteria
- hypertension due to other reasons (not pulmonary)
Data sourced from ClinicalTrials.gov (NCT00759408). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.